6mep
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC3437== | |
+ | <StructureSection load='6mep' size='340' side='right'caption='[[6mep]], [[Resolution|resolution]] 2.89Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[6mep]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEP OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MEP FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=9VS:cis-4-[(2-[(4-{[4-(1,3-dioxolan-2-yl)pyridin-2-yl]ethynyl}phenyl)amino]-5-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}pyrimidin-4-yl)amino]cyclohexan-1-ol'>9VS</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MERTK, MER ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
+ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6mep FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mep OCA], [http://pdbe.org/6mep PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6mep RCSB], [http://www.ebi.ac.uk/pdbsum/6mep PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6mep ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Disease == | ||
+ | [[http://www.uniprot.org/uniprot/MERTK_HUMAN MERTK_HUMAN]] Defects in MERTK are the cause of retinitis pigmentosa type 38 (RP38) [MIM:[http://omim.org/entry/613862 613862]]. RP38 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.<ref>PMID:11062461</ref> | ||
+ | == Function == | ||
+ | [[http://www.uniprot.org/uniprot/MERTK_HUMAN MERTK_HUMAN]] Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). Ligand binding at the cell surface induces autophosphorylation of MERTK on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3.<ref>PMID:17005688</ref> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Controlling which particular members of a large protein family are targeted by a drug is key to achieving a desired therapeutic response. In this study, we report a rational data-driven strategy for achieving restricted polypharmacology in the design of antitumor agents selectively targeting the TYRO3, AXL, and MERTK (TAM) family tyrosine kinases. Our computational approach, based on the concept of fragments in structural environments (FRASE), distills relevant chemical information from structural and chemogenomic databases to assemble a three-dimensional inhibitor structure directly in the protein pocket. Target engagement by the inhibitors designed led to disruption of oncogenic phenotypes as demonstrated in enzymatic assays and in a panel of cancer cell lines, including acute lymphoblastic and myeloid leukemia (ALL/AML) and nonsmall cell lung cancer (NSCLC). Structural rationale underlying the approach was corroborated by X-ray crystallography. The lead compound demonstrated potent target inhibition in a pharmacodynamic study in leukemic mice. | ||
- | + | Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.,Da C, Zhang D, Stashko M, Vasileiadi E, Parker RE, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, Earp HS, Graham DK, Frye SV, Wang X, Kireev D J Am Chem Soc. 2019 Oct 2;141(39):15700-15709. doi: 10.1021/jacs.9b08660. Epub, 2019 Sep 20. PMID:31497954<ref>PMID:31497954</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
- | [[Category: | + | <div class="pdbe-citations 6mep" style="background-color:#fffaf0;"></div> |
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Human]] | ||
+ | [[Category: Large Structures]] | ||
+ | [[Category: Receptor protein-tyrosine kinase]] | ||
[[Category: Cheng, A]] | [[Category: Cheng, A]] | ||
- | [[Category: Deryckere, D]] | ||
- | [[Category: Kireev, D]] | ||
- | [[Category: Graves, L]] | ||
[[Category: Da, C]] | [[Category: Da, C]] | ||
- | [[Category: | + | [[Category: DeRyckere, D]] |
- | [[Category: | + | [[Category: Earp, H S]] |
- | [[Category: | + | [[Category: Frye, S V]] |
- | + | [[Category: Graham, D K]] | |
- | [[Category: Graham, D | + | [[Category: Graves, L]] |
- | [[Category: | + | [[Category: Hunter, D]] |
- | [[Category: | + | [[Category: Kireev, D]] |
- | [[Category: | + | |
[[Category: Machius, M]] | [[Category: Machius, M]] | ||
+ | [[Category: Miley, M J]] | ||
+ | [[Category: Norris-Drouin, J]] | ||
+ | [[Category: Stashko, M A]] | ||
+ | [[Category: Wang, X]] | ||
+ | [[Category: Zhang, D]] | ||
+ | [[Category: Drug design]] | ||
+ | [[Category: Fibrinolytic agent]] | ||
+ | [[Category: Macrocyclic]] | ||
+ | [[Category: Model]] | ||
+ | [[Category: Molecular]] | ||
+ | [[Category: Protein kinase inhibitor]] | ||
+ | [[Category: Proto-oncogene protein]] | ||
+ | [[Category: Pyrimidine]] | ||
+ | [[Category: Structure-activity relationship]] | ||
+ | [[Category: Thrombosis]] | ||
+ | [[Category: Transferase-transferase inhibitor complex]] |
Revision as of 06:10, 10 October 2019
Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC3437
|
Categories: Human | Large Structures | Receptor protein-tyrosine kinase | Cheng, A | Da, C | DeRyckere, D | Earp, H S | Frye, S V | Graham, D K | Graves, L | Hunter, D | Kireev, D | Machius, M | Miley, M J | Norris-Drouin, J | Stashko, M A | Wang, X | Zhang, D | Drug design | Fibrinolytic agent | Macrocyclic | Model | Molecular | Protein kinase inhibitor | Proto-oncogene protein | Pyrimidine | Structure-activity relationship | Thrombosis | Transferase-transferase inhibitor complex